The management of hereditary transthyretin-mediated amyloidosis (hATTR) is important in the medical community, as patients suffer from serious associated symptoms, such as polyneuropathy, which calls for safe and efficacious agents to help slow the progression of the disease. This activity covers the proper use of inotersen contributes to the management of subsequent disease manifestations, including the importance of utilizing such targeted therapy, which, in turn, augments the patient treatment strategy.

**Objectives:**
- Describe the use of inotersen in treating polyneuropathy caused secondarily by hATTR.
- Summarize the adverse effects of inotersen and how they may be prevented or managed. 
- Describe the contraindications of inotersen and how to identify them in a patient.
- Summarize the indications, responsible prescription, and administration of inotersen in treating polyneuropathy caused by hATTR.